Cancer Research

Researchers have identified that inhibiting the Wee1 protein inadvertently disables a critical switch required for all fast-proliferating cells to begin the DNA replication process. For decades, the pharmaceutical industry has focused on Wee1 as a potential vulnerability for tumors that lack the

Current research into the long-term biological safety of nanoparticles is essential to address concerns regarding oxidative stress and potential cytotoxicity in human patients. This investigation is particularly vital as the medical and scientific community pivots toward the intersection of

The aggressive nature of triple-negative breast cancer often leaves clinicians with a narrow window for effective intervention due to its lack of hormone receptors and rapid metastatic progression. This specific subtype has historically bypassed traditional targeted therapies, necessitating a

The biological hurdles of treating solid tumors with T-cell therapy are being decoded through new findings linking tumor lesion diameters to the ultimate durability of the patient response. At the current Society for Immunotherapy of Cancer Annual Meeting, researchers presented updated data

Engineering T-cells to recognize multiple antigens allows the treatment to remain effective even if some tumor cells stop expressing one of the targeted markers. For families facing a pediatric Diffuse Midline Glioma (DMG) diagnosis, the news is historically grim, as this aggressive cancer

The development of cyclic peptides like FAP-2286 underscores the potential of fibroblast activation protein as a versatile pan-cancer target for molecular imaging. This approach has catalyzed a movement toward a more nuanced understanding of how radioactive isotopes can be harnessed to identify and